Stem Cell Therapeutics Publications
by
Walter P. Drake, N.D., Ph.D.
Featured papers
Supporting Bengal Bioscience
authored by Walter P. Drake
Please CLICK on a TITLE to read or download the research report:
November, 2024: “Application of Etaluma Immunofluorescence Microscope for Saliva Protein Analysis”, describing how the effectiveness of stem cell therapies could be exhibited by the quantitative testing of saliva growth factors and cytokines with fluorescent antibodies using the Etaluma immunofluorescence Microscope.
January, 2024: “Testing For Inflammatory Markers Associated With Most Diseases Treatable with Stem Cell Therapy”, indicating that the effectiveness of any stem cell therapeutic application could be shown to be effective by testing for relatively common inflammatory markers of serious medical conditions and disease
June, 2023: Intravenous High Dose Light Activated PRP Therapy, reviewed the then recent papers demonstrating therapeutic results following high does intravenous therapy with the patient’s platelet rich plasma (PRP) and detailing the appropriate protocol.In this report issued in June 2023, Dr. Drake and colleague Dr. Laurence Hicks D.O. were possibly the first to describe the entire protocol for Intravenous High Dose Light Activated PRP Therapy.
Although parts of the procedure were known, most if not all practitioners were focused in injecting low dose PRP for facial rejuvenation and joint repair. Almost no one was even vaguely thinking about Intravenous Platelet Rich Plasma, or the fact that it would become to be shown to be the pre-eminent therapeutic protocol that would surpass results using other stem cell modalities that had been developed internationally for over 20 years.
The paper includes the drawing depicting the procedure which begins by the collection of blood from a patient, and proceeds to concentrating the platelets by centrifugation, followed by the necessary light activation to release growth factors prior to re-injection back to the patient in about 1 hour:
This following is the original drawing of the protocol by Walter P. Drake in 2023. The protocol has since evolved to include FDA-approved PRP processing kits, pre/post-procedure saliva growth factor testing, and an upgraded platelet activation light box. This drawing was originally presented for peer discussion:
Since 2023, we now have a wide selection of FDA approved kits which allow for complete sterile, closed system processing of the patient’s PRP so as to avoid contamination. In addition, since that time, we now have additional reports have been published by others detailing the necessity of light activation of the platelets and associated small bodies so as to release the maximum amount of growth factors to wake up innate but dormant stem cells.
January, 2023: “Drake-Hicks Protocol For In Situ Release of Mesenchymal Stem Cells and Cytokines Following Abdominal Lipolysis”, discussing methodologies for melting abdominal fatty tissue in vivo by injection and other techniques so as to release stem cells from the fatty matrix into the general circulation, thus avoiding a mini-liposuction.
January, 2023: Stem Cell Therapy Without Stem Cells, concluding that since stem cells are resident in virtually every tissue and organ, the patient does not need any more stem cells. What the patient needs is the stimulation and activation of endogenous growth factors and cytokines that can come about from the in vivo stimulation by one or more means. Liposuction is just one means of injury, that most likely by itself, is causing the activation of innate stem cells without any need for re-injection of more autologous stem cells.
January, 2022: From a Tube of Blood To Exosomes…The Stem Cell Therapy Story 2022, being the Address to Graduate Students of the Panama College of Cell Science detailing the history of stem cell therapeutics from 2005 to 2022.
November, 2017: Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction, being the first paper published in the United States demonstrating stem cell therapy safety, using stem cells harvested from patients’ abdominal fat and transplanted back into the same patients with various medical conditions.
All Biomedical Publications
by
Walter P. Drake
A chronological collection of published biomedical research by Walter P. Drake, N.D., Ph.D., spanning over five decades and covering topics including tumor immunology, stem cell therapy, PRP protocols, and innovative methodologies in regenerative medicine.
1. Drake WP, Ungaro PC, and Mardiney MR Jr.: Preservation of Cellular Antigenicity of Tumor Cells by the Use of Formalin Fixation. Cancer Research 32:1042-1044, 1972.
2. Markham RV, Sutherland TC, Cimino EF, Drake WP, and Mardiney MR Jr.: Immune Complexes Localized in the Renal Glomeruli of AKR Mice: The Presence of MuLV gs-1 and C-Type RNA Tumor Virus gs-3 Determinants. European Journal of Clinical and Biological Research 17(7):11-15, 1972.
3. Ungaro PC, Drake WP, Buchholz DH, and Mardiney MR Jr: Alteration of Specificity of AntiTumor Antisera by the Use of Passively Administered Antibody. Cancer Research 32:1521-1525, 1972.
4. Drake WP, Ungaro PC, and Mardiney MR Jr: Formalin-Fixed Cell Preparations for Use in the Automated Trypan Blue Cytotoxic Assay. Transplantation 14:127-130, 1972.
5. Ungaro PC, Drake WP, and Mardiney MR Jr: The Formalinization of Antibody to Tumor Cells in Altering the Immune Response. Cancer Research 32:2241-2247, 1972.
6. Drake WP, Ungaro PC, and Mardiney MR Jr: The Measurement and Manipulation of Hemolytic Complement Levels in Tumor Bearing C57BL/6 Mice. Biomedicine 18:284-289, 1973.
7. Ungaro PC, Drake WP, and Mardiney MR Jr: Augmentation of Antitumor Antibody Activity by the Use of Lyophilization. Journal of the National Cancer Institute 50:201-204, 1973.
8. Ungaro PC, Drake WP, and Mardiney MR Jr: Repetitive Administration of Bacillus Calmette Guerin in the Treatment of Spontaneous Leukemia of AKR Mice. Journal of the National Cancer Institute 50:125-128, 1973.
9. Drake WP, Ungaro PC, and Mardiney MR Jr: The Passive Administration of Antiserum and Complement in Producing Anti-El4 Cytotoxic Activity in the Serum of C57BL/6 Mice. Journal of the National Cancer Institute 50:909-914, 1973.
10. Drake WP, and Mardiney MR Jr: The Enhancement of Antitumor Antibody Binding to Cross-Reactive Normal Tissue Antigens. Transplantation 16:189-198, 1973.
11. Drake WP, LeGendre SM, and Mardiney MR Jr: Depression of Complement Activity in Three Strains of Mice After Tumor Transfer. International Journal of Cancer 11:719-724, 1973.
12. Mardiney MR Jr, Ungaro PC, and Drake WP: Immunoprophylaxis and the Treatment of Leukemia in AKR Mice: Repetitive Use of BCG. National Cancer Institute Monograph, 39:89-90, 1973.
13. Drake WP, Cimino EF, Mardiney MR Jr, and Sutherland JC: Prophylactic Therapy of Spontaneous Leukemia of AKR Mice with Polyadenylic acid-Polyuridylic acid (Poly A:U). Journal of the National Cancer Institute 50:941-944, 1974.
14. Drake WP, and Mardiney MR Jr: Parameters of Serum Complement in Relation to Tumor Therapy. Biomedicine 21:206-209, 1974.
15. Drake WP, Pokorney DR, and Mardiney MR Jr: In Vivo Abrogation of C3 and C5 by Administration of Cobra Venom Factor and Heterologous Anti-C3. Journal of Immunological Methods 6: 61-72, 1974.
16. Drake WP, and Mardiney MR Jr: Complement Mediated Alteration of AntibodySpecificity in vivo. J. Immunol. 114: 1052-1057, 1975.
17. Drake WP, Roberts GC, Pendergrast WJ, and Mardiney MR Jr: The Kinetics of the Interaction of Heterologous Anti-Tumor Serum and Heterologous Complement in Non-Tumor Bearing Mice. Biomedicine 22(6): 502-508, 1975.
18. Drake WP, Pokorney DR, Chipman S, Levy CC, and Mardiney MR Jr: Elevated Ribonuclease Activity in the Thymus and White Blood Cells of Genetically Cancer Prone Mice. J. Experimental Med. 141: 918-923, 1975.
19. Drake WP, Kopyta LP, Levy CC, and Mardiney MR Jr: Alterations in Ribonuclease Activities in the Plasma, Spleen, and Thymus of Tumor-Bearing Mice. Cancer Research 35: 322-324, 1975.
20. Drake WP, Pokorney DR, Ruckdeschel JC, Levy CC, and Mardiney MR Jr: A White Blood Cell Ribonuclease Assay for the Possible Monitoring of Malignancy. J. Natl. Cancer Institute 54(6): 1475-1478, 1975.
21. Drake WP, Schmuckler M, Pendergrast WJ, Davis AS, Lichtenfeld JL, and Mardiney MR Jr: Abnormal Profile of Human Nucleolytic Activity as a Diagnostic Test For Cancer. J. Natl. Cancer Institute 55:1055, 1975.
22. Pendergrast WJ, Drake WP, and Mardiney MR Jr: The Dependence of Successful Immunotherapy on Adequate Tumor Burden. J Natl. Cancer Institute 55: 1223-1225, 1975.
23. Drake WP, Pendergrast WJ Jr., Kramer RE, and Mardiney MR Jr.: Enhancement of Spontaneous C3H/HeJ Mammary Tumorigenesis by Long-Term Polyadenylic-Polyuridylic Acid Therapy. Cancer Res. 35(11): 3051-3, 1975.
24. Drake WP, Pokorney DR, Kopyta LP, and Mardiney MR Jr.: In Vivo Decomplementation of Guinea Pigs with Cobra Venom Factor and Anti-C3 Serum: Analysis of the Requirement of C3 and C5 for Mediation of Endotoxin-Induced Death. Biomedicine Express 25(3): 91-94, 1976.
25. Drake WP, Pendergrast WJ Jr., Kramer RE, and Mardiney MR Jr.: The Age-Dependant Efficacy of Polyadenylic-Polyuridylic Acid Therapy Upon the Development of Spontaneous Leukemia in AKR Mice. Cancer Res. 36(3): 1172-5, 1976.
26. Pendergrast WJ Jr., Drake WP, and Mardiney MR Jr.: A Proper S
equence for the Treatment of B16 Melanoma: Chemothrerapy, Surgery, and Immunotherapy. J. Natl. Cancer Inst. 57(3): 539-44, 1976.
27. Drake WP, Roberts GC, and Mardiney MR Jr.: Latent Homology of Murine Lymphoid Antigens Revealed Through the Complement Mediated Absorption of Xenogenic Antiserum. Biomedicine 24(5): 329-33, 1976.
28. Ruckdeschel JC, Doukas JG, Drake WP, and Mardiney MR Jr.: Application of Laser Cytometry to the Analysis of Immunologically Induced In Vitro Lymphocyte Responsiveness. Transplantation 23(5): 396-403, 1977.
29. Drake WP, Frazier LM, Sidle D, and Mardiney, MR Jr.: Alteration of Cellular Ribonuclease Associated With Murine Oncogenic Virus Infection. Biomedicine 28: 24-28, 1978.
30. Drake WP: Use of Formalin to Create Cellular Environments for Stem Cell Differentiation. Letter to Michael R. Mardiney Jr. MD, September 23, 2007. Published online by Drake Biomedical Institute (DrakeBiomedicalInstitute.wordpress.com) at: https://drakebiomedicalinstitute.files.wordpress.com/2010/10/lettertomichael1.pdf
31. Comella K., Parlo M, Daly R, Depasquale V, Edgerton E, Mallory P, Schmidt R, Drake WP: Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction. J Clin Med Res 2017: 9(11): 935-942 [doi: https://doi.org/10.14740/jocmr3187w%5D Full Text: http://www.jocmr.org/index.php/JOCMR/article/view/3187/1954
32. Drake, WP and Hicks, LV Sr., “A Transdermal Formulation of Icariin for Use as a Substitute for Sildenafil and a Showing of No Clinical Efficacy”, International Journal of Science and Research (IJSR), 8(9): 939 – 943, 2019. https://www.ijsr.net/archive/v8i9/ART20201251.pdf
33. Drake, WP, “High Dose Vitamin A Cures Severe Acne Vulgaris”, International Journal of Science and Research (IJSR), 10(2): 687-691,2021.
34. Drake, WP, “From a Tube of Blood To Exosomes…The Stem Cell Therapy Story 2022”, Panama College of Cell Science-January 1, 2022; Published at https://panamacollegeofcellscience.org/2022/02/09/from-a-tube-of-blood-to-exosomesthe-stem-cell-therapy-story-2022/ Accessed March 7, 2022
35. Drake, Walter P: “Stem Cell Therapy Without The Stem Cells”, Panama College of Cell Science, Publisher, January 31, 2023 https://panamacollegeofcellscience.org/2023/02/01/stem-cell-therapy-without-the-stem-cells/ Accessed: January 31, 2023. Figshare. Journal contribution.
https://doi.org/10.6084/m9.figshare.21985202.v1
36. Drake, Walter P; Hicks, Sr., Laurence V. “Drake-Hicks Protocol For In Situ Release of Mesenchymal Stem Cells and Cytokines Following Abdominal Lipolysis”, Panama College of Cell Science, Publisher, January 31, 2023. https://panamacollegeofcellscience.org/2023/02/01/drake-hicks-protocol-for-in-situ-release-of-mesenchymal-stem-cells-and-cytokines-following-abdominal-lipolysis/
Accessed January 31, 2023. Figshare. Journal contribution.
https://doi.org/10.6084/m9.figshare.21985640.v1
37. Drake, Walter P; Hicks, Sr., Laurence V. (2023). 2023: “High Dose Light Activated PRP the New Stem Cell Therapy”. figshare. Journal contribution. https://doi.org/10.6084/m9.Figshare.23611734.v1
DOI: https://doi.org/10.6084/m9.figshare.23611734.v1
38. Drake, Walter P; Hicks, Sr., Laurence V. (2024). “Testing For Inflammatory Markers Associated With Most Diseases Treatable with Stem Cell Therapy”. ResearchGate. https://www.researchgate.net/publication/377266647_Testing_For_Inflammatory_Markers_Associated_With_Most_Diseases_Treatable_with_Stem_Cell_Therapy
39. Drake, Walter P., “Application of Etaluma Immunofluorescence Microscope for Saliva Protein Analysis”, International Journal of Science and Research (IJSR), 13(11): 86-93 (2024)
https://www.ijsr.net/archive/v13i11/SR241031024410.pdf
**********************************
